HCW Biologics announced that its new cancer immunotherapy drug, HCW11-040, was selected as one of the Top 150 abstracts at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC). HCW11-040 is a first-in-class fusion immunotherapeutic designed to rejuvenate exhausted T cells and convert cold tumors to hot tumors, showing superior preclinical results compared to pembrolizumab. This recognition highlights the drug's potential impact on cancer treatment by combining immune checkpoint blockade with immune activation. The company will present detailed data at the SITC meeting in November 2026, advancing its clinical development efforts.
HCW Biologics’ new cancer immunotherapy drug HCW11-040 was recognized for scientific rigor and potential impact. For readers following health-sector stocks, here is Pluang's market snapshot as of Nov 06, 2026 22:11 WIB: out of 150 priced US health stocks, 68 rose and 82 fell. Notable movers include HALO at USD 107.48 with a -12.59% change and a typical hold time of 3 days, NTRA at USD 320.29 with a -11.95% change and Pluang order activity showing 59% sell and 41% buy, and CGC at USD 0.62 with a -8.85% change and 100% sell order activity.
The Europe portable washing machine market is projected to grow from $2.52 billion in 2025 to $3.58 billion by 2034, with a CAGR of 3.98%. Growth is fueled by urban compact living, rising demand for space-saving appliances, increased consumer mobilit...
Food Lion has agreed to purchase five Winn-Dixie stores in Southern Georgia, expanding its presence to 51 stores in the state. This acquisition will bring Food Lion's total new store openings in 2026 to 15, exceeding its original target of 10. The st...
Cerebras Systems' stock fell 19.6% on June 24, 2026, after missing Q1 earnings estimates and revealing increased costs from renting third-party capacity. A subsequent report in October questioned the durability of Cerebras' chips and alleged inflated...
The global medical imaging workstations market is projected to grow from USD 6.20 billion in 2026 to USD 12.55 billion by 2036, at a CAGR of 7.3%. Growth is fueled by rising chronic disease prevalence, increased diagnostic imaging demand, and advance...
The global sacral neuromodulation market is projected to grow from $1.37 billion in 2026 to $3.92 billion by 2036, at an 11.1% CAGR. Growth is fueled by rising cases of urinary and fecal incontinence, demand for minimally invasive treatments, and an ...
